Categories
Uncategorized

Roswell Cancer Center praises Cuba´s VSSP cancer drug effectiveness

According to a collaborative effort among EPCCC researchers and Cuba´s Center for Molecular Immunology (CIM), it was created a new strategy to correct immune dysfunction in patients suffering from malignant tumors, the source said. 
The reports, which involved both lab studies and an early-phase clinical trial, showed that a new immune modulator (VSSP) can significantly reduce myeloid-derived suppressor cells (MDSC) among people with advanced kidney cancer.


Read More